The agency announces that it cannot conclude cannabidiol is GRAS, potentially heading off GRAS notifications and making NDI notifications a likelier future for CBD use in the supplement sector if any “lawful pathway” is to be found. In addition to a barrage of warning letters to marketers of CBD products, the FDA issued a stark warning to consumers about potential hazards.
Industry stakeholders were taken aback on 25 November by what is being read as an aggressive new stance from the US Food and Drug Administration on cannabidiol (CBD), on the heels of 15 warnings letters to marketers of unapproved CBD products.
“CBD has the potential to harm you, and harm can happen even before you become aware of it,” the agency...